"In just over a year ago, it's been estimated $50 billion was invested on pharmaceutical Research and Development activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth. Biotechnology and Pharmaceutical Companies with developments and recent market activity this week include: Moleculin Biotech, Inc., (NASDAQ: MBRX), XBiotech Inc. (NASDAQ: XBIT), GTx, Inc. (NASDAQ: GTXI), Agenus Inc. (NASDAQ: AGEN) and TrovaGene Inc. (NASDAQ: TROV)"
How many of these companies are applying research to the use of medicinal cannabis in the rising medicinal cannabis market? They are clearly focusing their attention on non-cannabis markets and will go through MYDX when the time is right for them which is most likely when medicinal cannabis is legal at the federal level. The more years, the more they will have to pay for all of MYDX's R&D investments in advanced medicinal cannabis vape pen. What effect will this have on current MYDX investors?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.